Mundipharma Presents Phase III Rezafungin Trial Results
The investigational antifungal drug met primary endpoints in a study of stem cell transplant patients.
Updated on Oct. 22, 2026 in Diseases — General
Live Poll
Do you believe new pharmaceutical trials for rare diseases prioritize patient safety over potential profit?
Mundipharma has released Phase III ReSPECT trial data for the investigational drug rezafungin, which aims to prevent invasive fungal diseases in stem cell transplant recipients. The study demonstrated the drug is non-inferior to standard antimicrobial treatments in fungal-free survival.
Why it matters
Patients undergoing allogeneic haematopoietic stem cell transplantation face significant risks from life-threatening invasive fungal infections. New prophylactic options are critical for improving outcomes in this vulnerable population.
The study randomized 402 patients to rezafungin and 200 to a standard regimen, achieving a 3.5% invasive fungal disease rate versus 4.5% for the control. Serious adverse events were reported in 66.0% of the rezafungin cohort compared to 67.5% for the standard group.
The players
Mundipharma
A global pharmaceutical company that develops and markets medicines across various therapeutic areas including respiratory, oncology, and pain management.
FDA
The United States Food and Drug Administration is responsible for protecting public health by regulating pharmaceuticals and medical devices.
EMA
The European Medicines Agency is a scientific body responsible for the evaluation and supervision of medicinal products in the European Union.
The details
Rezafungin was administered via a 400 mg intravenous loading dose followed by 200 mg once weekly, while the control group received daily oral azole and trimethoprim/sulfamethoxazole. Data from the ReSPECT trial has been submitted to both the FDA and the EMA for regulatory review.
Timeline
April 2026: Topline ReSPECT trial results were announced.
October 22, 2026: Phase III ReSPECT trial results were presented at IDWeek.
Q1 2027: The FDA target action date for the drug is scheduled.
The Big Picture
The ReSPECT Phase III trial follows a pattern set by standard antimicrobial research in hematology and transplant patients. This data marks the completion of the pivotal trial phase required for regulatory assessment of rezafungin's prophylaxis indication.
For patients undergoing stem cell transplantation, the eventual approval of this drug would provide a new option for preventing serious fungal complications. The current trial indicates a safety profile comparable to existing standard antimicrobial treatments.
The takeaway
Clinical trial data showing non-inferiority to standard regimens suggests rezafungin could become a viable prophylactic tool in transplant medicine. Stakeholders should monitor for regulatory updates in early 2027 to see if the drug receives authorization for this indication.
What happens next
The FDA is expected to reach a regulatory decision regarding the approval of rezafungin by the first quarter of 2027.
Further reading
Learn more about new medical developments in the Diseases — General section.
More information
View the FDA prescribing information for REZZAYO for technical details.
Live Poll
Do you believe new pharmaceutical trials for rare diseases prioritize patient safety over potential profit?
